Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT

Rakesh Heer,¹* Rebecca Lewis,² Anne Duncan,³ Steven Penegar,² Thenmalar Vadiveloo,³ Emma Clark,¹ Ge Yu,¹ Paramananthan Mariappan,⁴ Joanne Cresswell,⁵ John McGrath,⁶ James N’Dow,⁷ Ghulam Nabi,⁸ Hugh Mostafid,⁹ John Kelly,¹⁰ Craig Ramsay,¹¹ Henry Lazarowicz,¹² Angela Allan,¹³ Matthew Breckons,¹ Karen Campbell,³ Louise Campbell,³ Andy Feber,¹⁰ Alison McDonald,³ John Norrie,¹⁴ Giovany Orozco-Leal,¹ Stephen Rice,¹ Zafer Tandogdu,¹⁰ Ernest Taylor,¹⁵ Laura Wilson,¹ Luke Vale,¹ Graeme MacLennan³ and Emma Hall²

¹Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
²Clinical Trials and Statistics Unit, The Institute of Cancer Research, London, UK
³Centre for Healthcare Randomised Trials (CHaRT), University of Aberdeen, Aberdeen, UK
⁴Department of Urology, Western General Hospital, NHS Lothian, Edinburgh, UK
⁵Department of Urology, South Tees Hospitals NHS Trust, Middlesbrough, UK
⁶Department of Urology, Royal Devon and Exeter Hospital NHS Trust, Exeter, UK
⁷Academic Urology Unit, University of Aberdeen, Aberdeen, UK
⁸School of Medicine, University of Dundee, Dundee, UK
⁹Department of Urology, Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke, UK
¹⁰University College London Cancer Institute, University College London Hospitals NHS Foundation Trust, London, UK
¹¹Health Services Research Unit, University of Aberdeen, Aberdeen, UK
¹²Department of Urology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK
¹³Department of Urology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK
¹⁴Edinburgh Clinical Trials Unit, University of Edinburgh, Edinburgh, UK
¹⁵Tyne and Wear, UK

*Corresponding author rakesh.heer@newcastle.ac.uk
Declared competing interests of authors: Rakesh Heer is a member of the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Commissioning committee (2017–present). Paramananthan Mariappan reports honoraria, travel expenses, accommodation and non-financial support from Ipsen (Paris, France) and grants from Kyowa Kirin International (Galashiels, UK) outside the submitted work. Craig Ramsay is a member of HTA Board (2017–present). Henry Lazarowicz reports that urine samples from the Photodynamic versus white-light-guided resection of first diagnosis non-muscle-invasive bladder cancer—Translational (PHOTO-T) study were donated to the University of Liverpool for use in the Volatile Organic compounds in bladder cancer (VOID) translational research study; the author is a co-investigator on this study and the decision to collaborate and donate samples was made independently of the author’s presence on the Trial Management Group. John Norrie reports grants from the University of Aberdeen and the University of Edinburgh during the conduct of the study, and declares membership of the following NIHR boards: the Cardiopulmonary Resuscitation (CPR) Decision-making Committee (2016), HTA Commissioning Board (2010–16), HTA Commissioning Sub-Board [Expressions of Interest (EOI)] (2012–16), HTA Funding Boards Policy Group (2016), HTA General Board (2016–19), HTA Post-Board funding teleconference (2016–19), NIHR Clinical Trials Unit (CTU) Standing Advisory Committee (2017–present), NIHR HTA and Efficacy and Mechanism Evaluation (EME) Editorial Board (2014–19) and Pre-exposure Prophylaxis Impact Review Panel (2017–present). Luke Vale reports membership of the NIHR HTA programme’s Clinical Trials and Evaluation Panel (2014–18). Emma Hall reports grants from Accuray Inc. (Sunnyvale, CA, USA), Varian Medical Systems Inc. (Crawley, UK), Merck Sharp & Dohme (Kenilworth, NJ, USA), Sanofi SA (Paris, France) and Janssen-Cilag (Beerse, Belgium); grants and non-financial support from AstraZeneca plc (Cambridge, UK); grants and non-financial support from Bayer AG (Leverkusen, Germany); and grants and non-financial support from Roche Products Ltd (Welwyn Garden City, UK) outside the submitted work.

Published October 2022
DOI: 10.3310/PLPU1526

Scientific summary

The PHOTO RCT
Health Technology Assessment 2022; Vol. 26: No. 40
DOI: 10.3310/PLPU1526

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Around 7500 people are diagnosed with non-muscle-invasive bladder cancer (NMIBC) in the UK each year. Recurrence is common following treatment with transurethral resection of bladder tumour (TURBT), and the intensive monitoring schedule required after initial treatment has associated costs for the patient and the NHS. Recurrence is thought to be partially related to incomplete resection of the tumour. Photodynamic diagnosis (PDD) involves the intravesical instillation of a photosensitiser, which is preferentially absorbed by cancerous cells and causes the tumour to fluoresce under blue light, helping to guide TURBT. This technique offers better diagnostic accuracy and, therefore, may reduce the chance of subsequent recurrence.

Objectives

To compare the clinical effectiveness and cost-effectiveness of PDD resection with conventional white-light-guided transurethral resection of bladder tumour (WL-TURBT) for patients with newly diagnosed NMIBC who are at intermediate or high risk of recurrence.

Methods

Design

The Photodynamic versus white-light-guided resection of first diagnosis non-muscle-invasive bladder cancer (PHOTO) trial was a multicentre, pragmatic, open-label, parallel-group, non-masked, superiority randomised controlled trial that recruited from 22 NHS hospitals. Patients aged > 16 years with a first suspected diagnosis of intermediate- to high-risk NMIBC were invited to participate. Patients were excluded if they met any of the following exclusion criteria: visual evidence of low-risk NMIBC (solitary tumour < 3 cm in diameter) or muscle-invasive bladder cancer (MIBC) on preliminary cystoscopy; imaging evidence of MIBC (including the presence of hydronephrosis); upper tract (kidney or ureteric) tumours on imaging; any other malignancy in the past 2 years [except (for patients who have a life-expectancy of > 5 years at trial entry) non-melanomatous skin cancer cured by excision, adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ (DCIS)/lobular carcinoma in situ (LCIS) of the breast, or prostate cancer]; evidence of metastases; porphyria or known hypersensitivity to porphyrins; known pregnancy; any other contraindications to PDD or white-light (WL) surgery; and inability to provide informed consent or complete follow-up schedule [including health-related quality of life (HRQoL) questionnaires].

Interventions and randomisation

Eligible and consenting patients were allocated to receive either photodynamic diagnosis-guided transurethral resection of bladder tumour (PDD-TURBT) (i.e. the PDD group) or standard WL-TURBT (i.e. the WL group). All participants, unless there were clinical contraindications, received intravesical mitomycin C (40 mg in 40 ml of saline) after surgery and before discharge.

Treatment allocation used a 1 : 1 ratio and was conducted centrally by a remote web-based service, using a minimisation algorithm balanced by centre and sex.
Main outcome measures

**Primary outcome**
The primary outcome was time to recurrence of bladder cancer measured in months from randomisation to recurrence, including recurrence associated with progression to MIBC, cystectomy or death due to bladder cancer. The principal time point of interest was 3 years.

The primary health economic outcomes were cost-effectiveness, as determined by the incremental cost per recurrence avoided, and cost–utility, measured as the incremental cost per quality-adjusted life-year (QALY) gained at 3 years.

**Secondary outcomes**
Other clinical outcomes included adverse events (AEs) and complications up to 3 months from initial TURBT treatment. Direct, surgically related, postoperative events occurring within the 30 days following TURBT were assessed using the Clavien–Dindo classification for surgical complications [Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205–13]. Events occurring up to 3 months after TURBT were assessed and recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0 framework [National Cancer Institute. CTCAEs v4: *Common Terminology Criteria for Adverse Events* (CTCAE). Rockville, MD: National Cancer Institute; 2010. URL: https://ctep.cancer.gov/]. The relative changes in HRQoL resulting from the physical and psychological benefits, together with any harms associated with each strategy and subsequent necessary cancer treatment, were measured using the generic EuroQol-5 Dimensions, three-level version (EQ-5D-3L), questionnaire; the cancer-specific European Organisation for Research and Treatment of Cancer – Quality of Life Questionnaire – Core 30 (EORTC-QLQ-C30); and the disease-specific European Organisation for Research and Treatment of Cancer – Quality of Life Questionnaire – Non-Muscle Invasive Bladder Cancer – 24 items (EORTC-QLQ-NMIBC-24). These were completed by the participant on paper at baseline (prior to knowledge of treatment allocation), following surgery and at 3, 6, 12, 18, 24 and 36 months after randomisation. Disease progression was defined as an increase in stage to MIBC or the development of nodal or metastatic disease. Rates of overall survival and bladder-cancer-specific survival were compared between the two treatment groups. Other cost-effectiveness outcomes included estimation of the incremental cost per recurrence avoided using the economic model over the patient’s lifetime and estimation of the incremental cost per QALY gained using the economic model over the patient’s lifetime.

**Blinding**
Surgeons and participants could not be blinded to the allocated procedure.

**Sample size**
The trial aimed to detect an absolute reduction in recurrence at 3 years of 12%, from 40% (under the conservative assumption that all the patients recruited are intermediate-risk patients with a probability of recurrence of 0.4 at 3 years) to 28% (similar effect sizes of photodynamic therapy are reported in both intermediate- and high-risk groups); this is equivalent to a relative reduction of 30%. Power calculations were based on log-rank analysis of time-to-event data, translating an improvement in fixed-time point recurrence-free rate from 60% to 72% into a target effect size hazard ratio (HR) of 0.64. The recruitment of 533 participants (214 recurrences) would enable the detection of a HR of 0.64 between the experimental and control strategies and provide, using the log-rank test, 90% power at a two-sided 5% significance level. This calculation assumed 2.5 years of staggered recruitment (with 6%, 13%, 21%, 29% and 31% of the total number of patients recruited in each successive 6-month period); a minimum of 3 years’ follow-up; and cumulative follow-up attrition rates of 0.56% by the end of year 1, 1% at the end of year 2 and 6.4% at end of year 3, based on unpublished data from the Bladder cyclooxygenase 2 Inhibition Trial (BOXIT) (Professor Emma Hall, Institute of Cancer Research, 2012, personal communication).
**Statistical analysis**

The primary outcome was analysed using Cox proportional hazards regression models in which deaths were treated as censored. Additional analysis used accelerated failure time models, relaxing the proportional hazards assumption. A sensitivity analysis of the primary outcome treating deaths from non-bladder-cancer causes as a competing risk, rather than non-informative censoring, was performed. Secondary outcomes were analysed using the appropriate generalised linear models. The proportion of participants experiencing AEs (CTCAE grade 3 or above) was compared between groups using chi-squared tests or Fisher's exact test if expected cell frequencies were less than five. The number of AEs by Clavien–Dindo grade was tabulated by group.

**Economic evaluation**

At 3 years, the mean differences in costs to the NHS Personal Social Services and QALYs were estimated. QALYs were based on self-reported responses to the EQ-5D-3L administered at baseline and discharge, and sent by post at 3, 6, 12, 18, 24 and 36 months post randomisation. Cost-effectiveness was expressed as an incremental cost per QALY gained, and the net monetary benefit approach was used to identify the optimal treatment when the value of a QALY to society was £30,000. Estimates of cost-effectiveness were extrapolated to a lifetime using a microsimulation model. Sensitivity analysis explored the imprecision in estimates of costs and QALYs, as well as costs falling on participants and their families, wider societal costs, alternative ways to handle missing data and the impact of changing the discount rate.

**Results**

**Recruitment**

Between 11 November 2014 and 6 February 2018, 538 participants were randomised. Five participants were excluded as they were found to be ineligible following randomisation (four because of signs of MIBC or upper tract involvement on subsequent imaging and one for an unknown reason). After the initial TURBT, 29 participants were found to have no histological evidence of tumour, 60 had MIBC and 18 had an early cystectomy. These 107 participants were excluded from further analysis. There were 426 participants (209 in the PDD group and 217 in the WL group) in the final analysis population.

**Baseline and treatment received**

The groups were well balanced at baseline: the mean age was 70, 80% were men and > 80% of participants in each group were classified as being at intermediate risk. Two participants in each group did not receive surgery. All participants in the WL group received WL-TURBT; in the PDD group, 13 (6.3%) received WL-TURBT.

**Primary outcome**

The median follow-up time was 21 months for PDD and 22 months for WL group. Overall, there were 86 recurrences of bladder cancer in the PDD group and 84 in the WL group. The intention-to-treat (ITT) analysis of the primary outcome estimated a HR of 0.94 [95% confidence interval (CI) 0.69 to 1.28; p = 0.70]. The prespecified important difference, HR 0.64, was incompatible with the data. Relaxing the proportional hazards assumption using an accelerated failure time model based on log-normal distribution showed no evidence that the time ratio (TR) for trial participants differed between groups (TR 1.12, 95% CI 0.78 to 1.60; p = 0.550). The 3-year recurrence-free survival rates were 57.8% (95% CI 50.7% to 64.2%) in the PDD group and 61.6% (95% CI 54.7% to 67.8%) in the WL group, with an absolute difference of 3.8% (95% CI –5.59% to 13.37%).

**Secondary outcomes**

There were 19 bladder cancer progressions in the PDD group and 12 in the WL group (HR 1.41, 95% CI 0.67 to 2.96; p = 0.369). There were 16 deaths due to bladder cancer: eight in each group. There was no evidence that bladder-cancer-specific survival differed between the PDD and WL groups (subhazard ratio 0.80, 95% CI 0.37 to 1.72; p = 0.56).
There were 57 deaths: 27 in the PDD group and 30 in the WL group. Of the 57 participants who died, 16 (28.1%) died from bladder cancer, nine (15.8%) from cardiovascular events, nine (15.8%) from other cancers and 23 (40.4%) died of other causes. There was no difference in overall survival between the PDD and WL groups (HR 0.83, 95% CI 0.49 to 1.41; \( p = 0.496 \)). At 36 months, the mean score difference between the groups in EQ-5D-3L, was \(-0.013\) (99% CI \(-0.086\) to 0.061; \( p = 0.660 \)).

All the domains of the EORTC-QLQ-C30 and EORTC-QLQ-NMIBC-24 were similar over time. At 36 months, there was no evidence of a difference between the PDD and WL groups across all domains.

Eight participants had AEs (CTCAE grade 3 and above). There was no significant difference between the groups in the number of participants who experienced an AE: the number of participants who experienced an AE (CTCAE grade 3 and above) was 3 (1.4%) in the PDD group and 5 (2.3%) in the WL group \([\text{rate ratio (RR)} 0.62, 95\% \text{ CI 0.24 to 1.60; } p = 0.33]\).

**Economic evaluation**

At 3 years, on average, the total cost of PDD-TURBT was £12,881 per participant and the total cost of WL-TURBT was £12,005 per participant. There was no evidence of a statistically significant difference between the groups in the total NHS cost or the use of health services at 3 years. The incremental total NHS cost of PDD-TURBT compared with WL-TURBT was £876 (95% CI \(-£766\) to £2518). Widening the perspective of costs to include those falling on participants and families and wider societal costs reduced the incremental cost to £763 (95% CI £1048 to £2574), although there were no differences between treatment groups.

The average QALY gain at 3 years was 2.094 in the PDD group and 2.087 in the WL group (mean difference \(-0.007, 95\% \text{ CI } -0.133\) to 0.119). The probability of PDD-TURBT being considered cost-effective never exceeded 30% over the range of society's cost-effectiveness thresholds for a QALY considered from either an NHS/Personal Social Services perspective or a wider economic perspective. The results did not alter over the range of sensitivity analyses considered, except when it was assumed that the patient’s quality of life (QoL) for WL was 10% lower than the value for QoL used in the missing at random setting.

**Conclusions**

The PHOTO trial found no evidence of an improvement in clinical effectiveness associated with PDD. The cost-effective analysis demonstrated that PDD was not more cost-effective than WL at 3 years. Overall, the use of PDD-TURBT is not supported in the management of primary intermediate- to high-risk NMIBC.

**Future work**

Further work should include modelling appropriate surveillance schedules and exploring predictive and prognostic biomarkers.

**Trial registration**

This trial is registered as ISRCTN84013636.

**Funding**

This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) programme and will be published in full in *Health Technology Assessment*; Vol. 26, No. 40. See the NIHR Journals Library website for further project information.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/142/02. The contractual start date was in June 2014. The draft report began editorial review in February 2021 and was accepted for publication in July 2021. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health and Care Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, the HTA programme or the Department of Health and Social Care.

Copyright © 2022 Heer et al. This work was produced by Heer et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.

For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Dr Cat Chatfield  Director of Health Services Research UK

NIHR Journals Library Editors

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HSDR, PGfAR, PHR journals) and Editor-in-Chief of HSDR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Consultant in Public Health, Delta Public Health Consulting Ltd, UK

Dr Peter Davidson  Interim Chair of HTA and EME Editorial Board. Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Ms Tara Lamont  Senior Adviser, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Dr Catriona McDaid  Reader in Trials, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery  Professor of Health Technology Assessment, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Dr Rob Riemsma  Consultant Advisor, School of Healthcare Enterprise and Innovation, University of Southampton, UK

Professor Helen Roberts  Professor of Child Health Research, Child and Adolescent Mental Health, Palliative Care and Paediatrics Unit, Population Policy and Practice Programme, UCL Great Ormond Street Institute of Child Health, London, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk